Sign in

NCT06685185CompletedPhase 1

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

A Study Investigating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

Source: ClinicalTrials.gov · Last updated 9 Apr 2026

Brief summary (registry, in English)

This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes: Part 1A conducted in healthy participants and Part 1B conducted in participants with type 1 diabetes (T1D). This study part will last for about 1½ to 5½ weeks. Part 2 is a proof-of-principle (PoP) study part conducted in participants with T1D and will last for about 3½ to 8½ weeks. Part 3 is a meal test multiple dose study part conducted in participants with T1D and will last for 7 to 11 weeks.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
117 (actual)
First submitted
9 Nov 2024
Start date
12 Nov 2024
Primary completion date
8 Mar 2026
Lead sponsor
Novo Nordisk A/S
NCT number
NCT06685185
EU CT number
2024-511808-17-00
EudraCT number
2024-511808-17

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 117
  • From 12 Nov 2024 to the primary completion date, 8 Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
    • Part 1B SAD, Part 2 PoP and Part 3 Meal test (participants with T1D)
  • Any condition, except for mild conditions under stable treatment associated with type 1 diabetes mellitus, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

Age

  • Male of reproductive age who, or whose female partner(s), is not using an adequate contraceptive method.
  • Male of reproductive age who, or whose female partner(s), is not using an adequate contraceptive method.

Other

  • Part 1A SAD (healthy participants)

Who the study is looking for

  • Part 1A SAD (healthy participants)
  • Male or female of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Age 18-64 years (both inclusive) at the time of signing the informed consent.
  • Body mass index between 18.5-29.9 kilogram per square metre( kg/m\^2) (both inclusive) at the day of screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
    • Part 1B SAD, Part 2 PoP and Part 3 Meal test (participants with T1D)
  • Male or female of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Age 18-64 years (both inclusive) at the time of signing the informed consent.
  • Body mass index between 18.5-29.9 kg/m\^2 (both inclusive) at the day of screening.
  • Diagnosed with type 1 diabetes mellitus greater than or equal to( ≥)1 year prior to the day of screening.
  • Considered to be generally healthy (except for mild conditions under stable treatment associated with type 1 diabetes mellitus) based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Age in the registry: 18 years to 64 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
PROFIL Institut fuer Stoffwechselforschung GmbH
Coordinator of this site? Confirm its status
NeussGermanyCompleted

This page is information, not medical advice. Discuss any trial with your doctor.